Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

Mao Bin Meng, Huan Huan Wang, Nicholas G. Zaorsky, Xian Zhi Zhao, Zhi Qiang Wu, Bo Jiang, Yong Chun Song, Hong Qing Zhuang, Feng Tong Li, Lu Jun Zhao, Chang Li Wang, Kai Li, Ping Wang, Zhi Yong Yuan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC). Methods: Between 10/2006 and 7/2013, patients with R/SP-MLNMs originating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results: Thirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100% and 86%, respectively. Symptom alleviation was observed in 52% of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 = Grade 3 toxicities occurred in 5 patients (15%; all in Group B); among them, Grade 5 in 2 patients. Conclusions: We recommend exercising extreme caution in using SRT for R/SPMLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.

Original languageEnglish (US)
Pages (from-to)15690-15703
Number of pages14
JournalOncotarget
Volume6
Issue number17
DOIs
StatePublished - Jan 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Survival
Terminology
Databases
Prospective Studies
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Meng, Mao Bin ; Wang, Huan Huan ; Zaorsky, Nicholas G. ; Zhao, Xian Zhi ; Wu, Zhi Qiang ; Jiang, Bo ; Song, Yong Chun ; Zhuang, Hong Qing ; Li, Feng Tong ; Zhao, Lu Jun ; Wang, Chang Li ; Li, Kai ; Wang, Ping ; Yuan, Zhi Yong. / Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. In: Oncotarget. 2015 ; Vol. 6, No. 17. pp. 15690-15703.
@article{1fc86b6d79184ed6839230781d0706fd,
title = "Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer",
abstract = "Aims: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC). Methods: Between 10/2006 and 7/2013, patients with R/SP-MLNMs originating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results: Thirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100{\%} and 86{\%}, respectively. Symptom alleviation was observed in 52{\%} of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 = Grade 3 toxicities occurred in 5 patients (15{\%}; all in Group B); among them, Grade 5 in 2 patients. Conclusions: We recommend exercising extreme caution in using SRT for R/SPMLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.",
author = "Meng, {Mao Bin} and Wang, {Huan Huan} and Zaorsky, {Nicholas G.} and Zhao, {Xian Zhi} and Wu, {Zhi Qiang} and Bo Jiang and Song, {Yong Chun} and Zhuang, {Hong Qing} and Li, {Feng Tong} and Zhao, {Lu Jun} and Wang, {Chang Li} and Kai Li and Ping Wang and Yuan, {Zhi Yong}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3704",
language = "English (US)",
volume = "6",
pages = "15690--15703",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

Meng, MB, Wang, HH, Zaorsky, NG, Zhao, XZ, Wu, ZQ, Jiang, B, Song, YC, Zhuang, HQ, Li, FT, Zhao, LJ, Wang, CL, Li, K, Wang, P & Yuan, ZY 2015, 'Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer', Oncotarget, vol. 6, no. 17, pp. 15690-15703. https://doi.org/10.18632/oncotarget.3704

Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. / Meng, Mao Bin; Wang, Huan Huan; Zaorsky, Nicholas G.; Zhao, Xian Zhi; Wu, Zhi Qiang; Jiang, Bo; Song, Yong Chun; Zhuang, Hong Qing; Li, Feng Tong; Zhao, Lu Jun; Wang, Chang Li; Li, Kai; Wang, Ping; Yuan, Zhi Yong.

In: Oncotarget, Vol. 6, No. 17, 01.01.2015, p. 15690-15703.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

AU - Meng, Mao Bin

AU - Wang, Huan Huan

AU - Zaorsky, Nicholas G.

AU - Zhao, Xian Zhi

AU - Wu, Zhi Qiang

AU - Jiang, Bo

AU - Song, Yong Chun

AU - Zhuang, Hong Qing

AU - Li, Feng Tong

AU - Zhao, Lu Jun

AU - Wang, Chang Li

AU - Li, Kai

AU - Wang, Ping

AU - Yuan, Zhi Yong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aims: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC). Methods: Between 10/2006 and 7/2013, patients with R/SP-MLNMs originating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results: Thirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100% and 86%, respectively. Symptom alleviation was observed in 52% of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 = Grade 3 toxicities occurred in 5 patients (15%; all in Group B); among them, Grade 5 in 2 patients. Conclusions: We recommend exercising extreme caution in using SRT for R/SPMLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.

AB - Aims: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC). Methods: Between 10/2006 and 7/2013, patients with R/SP-MLNMs originating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results: Thirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100% and 86%, respectively. Symptom alleviation was observed in 52% of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 = Grade 3 toxicities occurred in 5 patients (15%; all in Group B); among them, Grade 5 in 2 patients. Conclusions: We recommend exercising extreme caution in using SRT for R/SPMLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84934283312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934283312&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3704

DO - 10.18632/oncotarget.3704

M3 - Article

C2 - 25881546

AN - SCOPUS:84934283312

VL - 6

SP - 15690

EP - 15703

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -